Abstract:Introduction: Structure-based drug design is a wide area of identification of selective inhibitors of a target of interest. From the time of the availability of three dimensional structure of the drug targets, mostly the proteins, many computational methods had emerged to address the challenges associated with drug design process. Particularly, drug-likeness, druggability of the target protein, specificity, off-target binding, etc., are the important factors to determine the efficacy of new chemical inhibitors. Objective: The aim of the present research was to improve the drug design strategies in field of design of novel inhibitors with respect to specific target protein in disease pathology. Recent statistical machine learning methods applied for structural and chemical data analysis had been elaborated in current drug design field. Methods: As the size of the biological data shows a continuous growth, new computational algorithms and analytical methods are being developed with different objectives. It covers a wide area, from protein structure prediction to drug toxicity prediction. Moreover, the computational methods are available to analyze the structural data of varying types and sizes of which, most of the semi-empirical force field and quantum mechanics based molecular modeling methods showed a proven accuracy towards analysing small structural data sets while statistics based methods such as machine learning, QSAR and other specific data analytics methods are robust for large scale data analysis. Results: In this present study, the background has been reviewed for new drug lead development with respect specific drug targets of interest. Overall approach of both the extreme methods were also used to demonstrate with the plausible outcome. Conclusion: In this chapter, we focus on the recent developments in the structure-based drug design using advanced molecular modeling techniques in conjunction with machine learning and other data analytics methods. Natural products based drug discovery is also discussed.

Recent advances in multitarget-directed ligands via in silico drug discovery

Recent Advances In The Rational Drug Design Based On Multi-Target Ligands

Recent Advances in the Rational Drug Design Based on Multi-target Ligands.

Advances in Computational Structure-Based Drug Design and Application in Drug Discovery.

Advancement of Multi-Target Drug Discoveries and Promising Applications in the Field of Alzheimer's Disease.

Computational Multitarget Drug Design.

Multi-target-directed-ligands acting as enzyme inhibitors and receptor ligands

In-Silico Approaches to Multi-target Drug Discovery

Recent advances in multitarget-directed ligands targeting G-protein-coupled receptors

What are the challenges with multi-targeted drug design for complex diseases?

Design of Multitarget Ligands with an Iterative Fragment-Growing Strategy.

Computer Aided Multi-target Drug Design, Multi-target Virtual Screening

In silico Strategy: A Promising Implement in the Development of Multitarget Drugs against Neurodegenerative Diseases.

Systematic Investigation of Dual-Target-Directed Ligands

Recent advances and method development for drug target identification

Application Advances on Novel Techniques in Multi-target Drugs Discovery

AI for targeted polypharmacology: The next frontier in drug discovery

Recent Trends in Drug Design and Discovery

How to design multi-target drugs: Target search options in cellular networks

Structure-based drug design: From nucleic acid to membrane protein targets

Rethinking therapeutic strategies of dual‐target drugs: An update on pharmacological small‐molecule compounds in cancer